Cancer

Titlesort descending Average Rating
Anti-angiogenic therapies for metastatic colorectal cancer. 60.00%
Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo 60.00%
Case report of a pituitary macroadenoma treated with artemether. 50.00%
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 80.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer. 40.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. 80.00%
How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. 80.00%
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and 50.00%
Inhibition of MIF Leads to Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells. 40.00%
Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. 80.00%
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. 70.00%
N-acetylcysteine inhibits proliferation, adhesion, migration and invasion of human bladder cancer cells. 80.00%
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofe 50.00%
Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of 60.00%
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre 70.00%
Durable responses with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with recurrent mantle cell lymphoma 70.00%
Ukrain, an alkaloid thiophosphoric acid derivative of Chelidonium majus L. protects human fibroblasts but not human tumour ce 80.00%
Chemical analyses of Ukrain, a semi-synthetic Chelidonium majus alkaloid derivative, fail to confirm its trimeric structure 90.00%
In vitro and in vivo antiproliferative activity of laherradurin and cherimolin-2 of Annona diversifolia Saff. 40.00%
Medicinal plants and cancer chemoprevention. 90.00%
A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort 80.00%
A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followe 30.00%
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts. 40.00%
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. 50.00%
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. 70.00%
Artesunate in the treatment of metastatic uveal melanoma--first experiences. 90.00%
Beta-solamarine: tumor inhibitor isolated from Solanum dulcamara. 60.00%
Brain tumour cells killed by anti-nausea drug 70.00%
Clinical management of adrenocortical carcinoma 60.00%
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a stu 70.00%
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-indep.. 70.00%
Effects of CANELIM capsule drug-contained serum on viscoelasticity 90.00%
Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer........ 0.00%
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m 60.00%
Gallic acid, a major component of Toona sinensis leaf extracts, contains a ROS-mediated anti-cancer activity in human prostate 60.00%
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds 80.00%
Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. 60.00%
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. 80.00%
Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. 70.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
Randomized Trials of Selenium, Vitamin E, or Vitamin C for Prostate Cancer Prevention 90.00%
Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal...... 60.00%
SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel 60.00%
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. 80.00%
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer 70.00%
The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary 50.00%
To widen the setting of cancer patients who could benefit from metronomic capecitabine. 80.00%
Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic soli 90.00%
Ukrain (NSC-631570) in the treatment of pancreas cancer. 95.00%
Ukrain (NSC-631570) influences on bone status: a review. 50.00%
Unconventional anticancer agents: a systematic review of clinical trials. 60.00%
WITHDRAWN: Multi-agent chemotherapy for early breast cancer. 0.00%
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and 90.00%
3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue. 100.00%
42 year old man. Kidney cancer 90.00%
61 year old woman, Breast cancer with lymph, and lung metastasis 90.00%
63 year old woman with stage III malignant melanoma 100.00%
66 year man. Cholangiocarcinoma 80.00%
71 year old woman, Pancraetic cancer with liver and lung metastasis. 90.00%
71 year old woman. Breast cancer with bone metastasis 90.00%
75 year old man, Prostate Cancer with bone and liver metastasis 100.00%
82 year old man with prostate cancer 85.00%
82 year old woman. Breast cancer with lymph and bone metastasis. 80.00%
A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. 90.00%
A case of metronomic chemotherapy as an alternative cancer therapy for palliation 60.00%
A comparative evaluation of the influence of the complex drug Ukrain and its components on the effects of radiation 80.00%
A homeopathic approach to treat patients with advanced gallbladder, periampullary, and liver carcinomas: a report of 3 cases. 90.00%
A lipoxygenase inhibitor in breast cancer brain metastases. 80.00%
A method for determination of Ukrain in blood plasma for monitoring and pharmacokinetic study 50.00%
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin.... 50.00%
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses 70.00%
A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients............... 50.00%
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. 50.00%
A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. 40.00%
A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. 50.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... 60.00%
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot 70.00%
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. 60.00%
A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma 80.00%
A phase II study of two dosing regimens of GSK 1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillar... 30.00%
A phase II trial of an adenovirus/PSA vaccine for prostate cancer. 70.00%
A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC) 50.00%
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with metastatic bladder cancer. 100.00%
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable m 100.00%
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with unresectable metastatic colorectal carcinoma. 100.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced esoph 90.00%
A phase II, single-arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with advanced non-s 100.00%
A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell.. 50.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi 60.00%
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal 100.00%
A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group. 80.00%
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung 50.00%
A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients ..... 90.00%
A study of the influence of a novel drug Ukrain on in vivo effects of low-dose ionizing radiation 50.00%
A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. 90.00%
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. 50.00%
Active specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized, renal adenocarcinoma pat 100.00%

Pages